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Temporin LIn order to enhance the membrane disruption of antimicrobial peptides both targeting and multivalent pre-
sentation approaches were explored. The antimicrobial peptides anoplin and temporin L were conjugated via
click chemistry to vancomycin and to di- and tetravalent dendrimers. The vancomycin unit led to enhanced
membrane disruption of large unilamellar vesicles (LUVs) displaying the vancomycin target lipid II, but only
for temporin L and not for anoplin. The multivalent presentation led to enhanced LUV membrane disruption
in the case of anoplin but not for temporin L.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Antimicrobial peptides (AMPs) are widespread throughout nature,
and serve as an inspiration for the development ofmembrane disruptive
compounds [1–4] asmanyof the knownAMPs kill bacteria by permeabi-
lizing the cytoplasmic membrane [5]. The promise of AMPs is that they
hardly induceresistance, sinceabacteriumcannoteasilychange itsmem-
brane to such an extent that AMPs no longer work. On the other hand
there are features that limit their potential biomedical application.
These include their limited in vivo stability, the relatively high dose re-
quired and concomitantly their insufﬁcient selectivity illustrated by
their frequent induction of hemolysis [1]. Nature has used targeting as a
way to enhance thepotencyof certainAMPs, such as nisin.Nisin contains
a lipid II binding portion that makes it perform at nano- rather thanmi-
cromolar concentrations [6–8]. This principle was recently mirrored in
a synthetic system capable of more rapid and speciﬁc bacterial killing
by taking advantage of incorporating a speciﬁcally binding peptide por-
tion. However, the targeting peptide did not seem to act independently
but ratherwasan integral part of the overall amphipathic permeabilizing
peptide, complicating its true mode of action [9,10]. Besides targeting, a
multivalentpresentation of AMPshas also been shown to enhancemem-
branedisruption, inaddition toenhancing in vivo stabilityeffects [11–14].arch, Ben Gurion, University of
rights reserved.This multivalency principle is also prevalent in nature, particularly
among AMPs acting together to form membrane pores [15]. A dendritic
presentation of multiple copies of the 23-mer peptide magainin previ-
ously showed greatly enhanced membrane disruption, although at the
expense of selectivity [16]. In order to explore the targeting andmultiva-
lency effects short AMP's were selected: anoplin and temporin L. These
AMP's are (partially)α -helicalandsomeof the shortest antimicrobial se-
quences known, which is an attractive feature for further development.
Anoplin (H-GLLKRIKTLL-NH2) originated from the venom of the solitary
wasp, contains 4 positive charges, and is amphipathic when helical, e.g.
in the presence of TFE or SDS [17]. Temporin L (H-FVQWFSKFLGRIL-
NH2) is derived from the European red frog and contains 3 positive
charges [18,19]. We here show the effects of both the targeting and the
multivalency approaches on the potency of our AMPs in disrupting LUV
membranes. A striking dependence on the sequence was observed. In
the ﬁrst approach the attachment of a targeting moiety, vancomycin in
this case, showed a clear potency enhancement in the pore forming ac-
tion of temporin L, but not of anoplin. In the second approach a tetrava-
lent presentation by linking the peptides to a dendritic core clearly
resulted in enhanced pore formation for anoplin but not temporin L.
2. Material and methods
2.1. General
Nisin was puriﬁed from Chrisin® (Christian Hansen). The vesicle
preparation and leakage studies were performed as described in Ref.
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the lipids.
2.2. Synthesis of 1 and 2
The antimicrobial peptides Anoplin(N3)-NH2 (1) and Temporin(N3)-
NH2 (2) were synthesized using automatic solid phase peptide synthe-
sis (SPPS) using the Fmoc/tBu-protocol. Fmoc-protected S-ram tengagel
resin was used. Fmoc-Lys(N3)-OH was previously synthesized accord-
ing to Ref. [16]. A step by step coupling of Fmoc protected amino acids
was used and deprotection was carried out using piperidine. After
synthesis the last deprotection was checked by Kaiser test [20] and
an additional BPB test [21]. After the positive control (successful ﬁnal
deprotection) the resin was swollen (DCM) and the peptides were
cleaved off the resin (using a cocktail of TFA:H2O:TIS 95:2.5:2.5 v/v/v)
and lyophilized,which yielded a crude peptide as a ﬂuffywhite powder.
The crude was puriﬁed in parts of 25 mg by preparative HPLC (C8,
MeCN buffers) and consequently lyophilized and analyzed for purity
(HPLC, C8, MeCN) and identity (ESI-MS).
3. Results and discussion
The AMPs were synthesized by automated solid phase peptide
synthesis using the Fmoc/tBu protocol on S-ram tentagel. The ﬁrst
amino acid was in both cases Fmoc-Lys(N3)-OH [16], to yield theFig. 1. Structures of the AMPs (1–2) and the dendriticpeptides anoplin(N3)-NH2 (1) and temporin(N3)-NH2 (2) (Fig. 1),
whose azide group on the modiﬁed lysine residues allows the use
of CuAAC click chemistry for conjugation to the vancomycin and
dendritic compounds. To this end vancomycin was linked to a spac-
er at its C-terminus which was outﬁtted with an alkyne moiety, to
yield 3 [22]. Finally the dendritic scaffolds 4 and 5 were prepared
as before [16].
The vancomycin conjugates of the two AMPs were prepared
using CuAAC click chemistry [16,23] and yielded 6 and 7 after pre-
parative HPLC puriﬁcation (Scheme 1). Subsequently both peptides
were linked to both the divalent and tetravalent scaffolds 4 and 5.
In all cases it was possible to obtain the products after preparative
HPLC puriﬁcation.
In order to evaluate the effect of targeting the AMPs by vancomy-
cin conjugation or by multivalency through dendrimer conjugation, a
membrane disruption assay was employed [16]. To this end large uni-
lamellar vesicles (LUVs) composed of the neutral phospholipid DOPC
or a 1:1 mixture of DOPC with the negatively charged phospholipid
DOPG were prepared containing 5(6)-carboxyﬂuorescein. These
LUVs were treated with the peptides and their conjugates. Disruption
of the membrane leads to a ﬂuorescent increase since the ﬂuores-
cence of the leaked 5(6)-carboxyﬂuorescein is no longer limited by
self-quenching inside the vesicle. The amount of leakage is expressed
as a percentage of the maximum leakage, which is induced by the
ﬁnal addition of Triton X-100. In order to evaluate the targeting effectscaffolds (3–4) used for CuAAC click conjugation.
Scheme 1. Conjugation of the AMP reagents and conditions: a) CuSO4, Na ascorbate, DMF/H2O, 80 °C, 79% for 6, 25% for 7; b) CuSO4, Na ascorbate, TBTA, DMF/H2O, 80 °C, 24% for 8,
25% for 9; and c) for 10: CuSO4, Na ascorbate, TBTA, DMF/H2O, 80 °C, 13% and for 11: CuOAc, TBTA, DMF, 100 °C, 27%.
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LUVs. Lipid II is a membrane embedded precursor of the bacterial
cell wall and the target of vancomycin. The results are shown in
Fig. 2–4.
In the ﬁrst experiments LUVs were used that incorporated lipid II.
Anoplin at lowmicromolar concentration was able to partially disrupt
the membrane, however the addition of the vancomycin moiety es-
sentially makes the compound inactive (Fig. 2). In contrast, temporin
L by itself showed very minor activity at 0.8 μM, whereas its conjuga-
tion to vancomycin greatly enhanced the activity, even though theFig. 2. Leakage results of 5(6)-carboxyﬂuorescein from mixed DOPC/DOPG vesicles
containing lipid II as caused by anoplin and temporin L, their vancomycin-linked deriv-
atives and nisin. Columns: 1: anoplin (0.8 μM); 2: anoplin (3.5 μM); 3: compound 6
(0.7 μM); 4: compounds 6 (3.3 μM); 5: temporin L (0.8 μM); 6: compound 7
(0.8 μM); and 7: nisin (0.1 μM).experiment with the anoplin–vanomycin conjugate had shown that
the vanomycin moeity, known to bind lipid 2, is not sufﬁcient to en-
able enhance membrane disruption. The antimicrobial peptide nisin,
whose activity is known to beneﬁt from its binding to lipid II [6],
was tested for comparison in this assay. The AMP–dendrimer conju-
gates were subsequently tested. They were tested with both the neu-
tral DOPC and the negatively charged mixed DOPC/DOPG LUVs (Fig. 3
and 4). The results were very similar. In order to make a fair compar-
ison the overall peptide concentration was kept the same when com-
paring mono- to di- to tetravalent, reducing the concentration of theFig. 3. Leakage results of 5(6)-carboxyﬂuorescein from mixed DOPC/DOPG vesicles as
caused by mono- and multivalent anoplin and temporin L. Columns: 1: anoplin
(2.0 μM); 2: compound 8 (1.0 μM); 3: compound 10 (0.5 μM); 4: compound 10
(0.05 μM); 5: temporin L (1.0 μM); 6: compound 9 (0.5 μM); and 7: compound 11
(0.25 μM).
Fig. 4. Leakage results of 5(6)-carboxyﬂuorescein from DOPC vesicles as caused by
mono- and multivalent anoplin and temporin L. Columns: 1: anoplin (2.0 μM); 2: com-
pound 8 (1.0 μM); 3: compound 10 (0.189 μM); 4: temporin L (1.0 μM); 5: compound 9
(0.5 μM); and 6: compound 11 (0.25 μM).
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mixed DOPC/DOPG LUVs anoplin showed only minor activity at
2.0 μM. The activity greatly increased when moving to the divalent
8 and especially to the tetravalent 10, while keeping the concentra-
tion of peptide the same in these experiments. The results were
very similar with the DOPC LUVs. Compound 10 induced almost
100% leakage at submicromolar concentrations, 189 and 500 nM, for
the two types of LUVs, while a 50 nM concentration still induced a
33% leakage of the mixed DOPC/DOPG LUVs. The situation was very
different for the temporin L conjugates. In these experiments the
leakage temporin L induced was only slightly surpassed by the two
dendritic conjugates 9 and 11.
The observed differences in behavior between the two peptide se-
quences in response to targeting and multivalency are striking. From
previous studies on anoplin it was concluded that the membrane dis-
rupting activity correlates with its degree of helicity and therefore
amphipathicity [24]. A study focused on the mechanism of action con-
cluded that a ‘toroidal pore’model is the most likely [25]. In a study of
temporin L and its derivatives both ‘carpet-like’ and ‘barrel-stave’
pore models have been implicated [26,27]. Although these models
are different, the differences are not big enough to a priori predict ei-
ther of the studied AMP sequences to beneﬁt or not beneﬁt from ei-
ther targeting or a multivalent display.
4. Conclusions
It is clear that targeting of AMP's can enhance their membrane
puncturing potency. Their multivalent presentation can do the
same. Either method is promising and may hold the key to enhanced
potency and speciﬁcity in antimicrobial or other biomedical applica-
tions. So far it has not yet been possible to combine the two effects
into a single molecule in order to maximize membrane disruption po-
tency. Whether the two phenomena remain mutually exclusive re-
mains to be seen.
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